JP6918204B2 - アルキル硫酸ナトリウムを含む医薬組成物 - Google Patents

アルキル硫酸ナトリウムを含む医薬組成物 Download PDF

Info

Publication number
JP6918204B2
JP6918204B2 JP2020507802A JP2020507802A JP6918204B2 JP 6918204 B2 JP6918204 B2 JP 6918204B2 JP 2020507802 A JP2020507802 A JP 2020507802A JP 2020507802 A JP2020507802 A JP 2020507802A JP 6918204 B2 JP6918204 B2 JP 6918204B2
Authority
JP
Japan
Prior art keywords
mass
compound
lauryl sulfate
sodium lauryl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020507802A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019181876A1 (ja
Inventor
憲司 楠本
憲司 楠本
定弘 宮村
定弘 宮村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JPWO2019181876A1 publication Critical patent/JPWO2019181876A1/ja
Priority to JP2021118771A priority Critical patent/JP7322103B2/ja
Application granted granted Critical
Publication of JP6918204B2 publication Critical patent/JP6918204B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020507802A 2018-03-19 2019-03-18 アルキル硫酸ナトリウムを含む医薬組成物 Active JP6918204B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021118771A JP7322103B2 (ja) 2018-03-19 2021-07-19 アルキル硫酸ナトリウムを含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018051620 2018-03-19
JP2018051620 2018-03-19
PCT/JP2019/011251 WO2019181876A1 (ja) 2018-03-19 2019-03-18 アルキル硫酸ナトリウムを含む医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021118771A Division JP7322103B2 (ja) 2018-03-19 2021-07-19 アルキル硫酸ナトリウムを含む医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2019181876A1 JPWO2019181876A1 (ja) 2020-10-08
JP6918204B2 true JP6918204B2 (ja) 2021-08-11

Family

ID=67987327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020507802A Active JP6918204B2 (ja) 2018-03-19 2019-03-18 アルキル硫酸ナトリウムを含む医薬組成物
JP2021118771A Active JP7322103B2 (ja) 2018-03-19 2021-07-19 アルキル硫酸ナトリウムを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021118771A Active JP7322103B2 (ja) 2018-03-19 2021-07-19 アルキル硫酸ナトリウムを含む医薬組成物

Country Status (22)

Country Link
US (1) US11833151B2 (enExample)
EP (3) EP4353222A1 (enExample)
JP (2) JP6918204B2 (enExample)
KR (1) KR102473372B1 (enExample)
CN (1) CN111867594A (enExample)
AU (1) AU2019239404B2 (enExample)
BR (1) BR112020018697A2 (enExample)
CA (1) CA3094431C (enExample)
DK (1) DK3769765T3 (enExample)
ES (1) ES2980333T3 (enExample)
FI (1) FI3769765T3 (enExample)
HU (1) HUE067430T2 (enExample)
MA (1) MA52093A (enExample)
MX (1) MX2020009762A (enExample)
MY (1) MY203305A (enExample)
PH (1) PH12020551412A1 (enExample)
PL (1) PL3769765T3 (enExample)
PT (1) PT3769765T (enExample)
RU (1) RU2759746C1 (enExample)
SG (1) SG11202008435SA (enExample)
TW (1) TWI790364B (enExample)
WO (1) WO2019181876A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021167346A (ja) * 2018-03-19 2021-10-21 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2020110974A1 (ja) * 2018-11-26 2020-06-04 大鵬薬品工業株式会社 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
WO2023238929A1 (ja) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 ピミテスピブを含有する医薬組成物

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3433239A1 (de) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
WO1998047499A1 (en) * 1997-04-22 1998-10-29 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
NZ524120A (en) 2000-07-19 2005-08-26 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
PL401638A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
ATE495155T1 (de) 2003-11-19 2011-01-15 Array Biopharma Inc Heterocyclische inhibitoren von mek
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
RU2364596C2 (ru) 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
CA2582247C (en) 2004-10-20 2014-02-11 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
AU2006257273A1 (en) * 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(ARyl-Or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists
ES2481402T3 (es) 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
ATE504565T1 (de) 2005-10-07 2011-04-15 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
US7659274B2 (en) 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
MX2008013675A (es) 2006-04-26 2009-03-06 Supernus Pharmaceuticals Inc Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal.
EP1939197A1 (en) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
NZ579911A (en) 2007-03-28 2012-05-25 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
PL2203181T3 (pl) 2007-10-16 2018-07-31 Biocon Limited Podawana doustnie stała kompozycja farmaceutyczna i jej sposób
CN102123989A (zh) 2008-06-19 2011-07-13 阿斯利康(瑞典)有限公司 吡唑化合物436
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
EA020017B1 (ru) 2009-04-30 2014-08-29 Новартис Аг Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011115937A1 (en) 2010-03-14 2011-09-22 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
DE102011015188A1 (de) 2010-03-29 2011-09-29 Herbert Kannegiesser Gmbh Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen
WO2011122620A1 (ja) * 2010-03-29 2011-10-06 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
TWI525097B (zh) 2011-04-06 2016-03-11 Taiho Pharmaceutical Co Ltd Novel imidazole and A compound or a salt thereof
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
EP2657233B1 (en) 2012-01-19 2014-08-27 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
RU2618423C2 (ru) 2012-07-02 2017-05-03 Тайхо Фармасьютикал Ко., Лтд. Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
BR112015012051A2 (pt) 2012-11-26 2017-12-12 Roche Innovation Ct Copenhagen As composições e métodos para modulação de expressão de fgfr3
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
PL3012327T3 (pl) 2013-06-20 2021-04-19 Taiho Pharmaceutical Co., Ltd. Sposób przewidywania skuteczności terapeutycznej inhibitora PI3K/AKT/mTOR na podstawie ekspresji PHLDA1 lub PIK3C2B
EP3023100B1 (en) 2013-07-18 2019-03-13 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor
TW201536293A (zh) 2013-07-18 2015-10-01 Taiho Pharmaceutical Co Ltd 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥
WO2015150900A2 (en) * 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
EP4397659A3 (en) 2014-04-25 2024-10-02 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
US10481946B2 (en) * 2014-05-12 2019-11-19 Hitachi, Ltd. Information-processing device, processing method thereof, and input/output device
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41350A (fr) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN105859721B (zh) 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法
CN112494653A (zh) 2015-02-05 2021-03-16 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
WO2016130917A1 (en) 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
JPWO2016136928A1 (ja) 2015-02-27 2017-08-31 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
PT3279202T (pt) 2015-03-31 2020-08-31 Taiho Pharmaceutical Co Ltd Cristal de composto de alquinilo de benzeno 3,5-dissubstituído
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016286091B2 (en) 2015-06-29 2021-02-04 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
JP2018524010A (ja) * 2015-07-24 2018-08-30 デバイオファーム インターナショナル エスエイ Ｆｇｆｒ発現とｆｇｆｒ阻害剤に対する感受性
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6860919B2 (ja) 2015-11-19 2021-04-21 国立大学法人金沢大学 間葉系ｋｒａｓ変異型がん治療剤
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
JP2018002662A (ja) 2016-07-01 2018-01-11 大鵬薬品工業株式会社 キノリルピロロピリミジル縮合環化合物を合成するために有用な中間体
JP6296308B1 (ja) 2016-09-26 2018-03-20 ツジカワ株式会社 ロール装置
JP7503380B2 (ja) 2017-01-10 2024-06-20 ノバルティス アーゲー Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬
EP4353222A1 (en) * 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
US20210387990A1 (en) 2018-11-09 2021-12-16 Taiho Pharmaceutical Co., Ltd. Method for producing dimethoxybenzene compound
KR102742083B1 (ko) 2018-11-09 2024-12-16 다이호야쿠힌고교 가부시키가이샤 디메톡시벤젠 화합물의 제조 방법
WO2020110974A1 (ja) 2018-11-26 2020-06-04 大鵬薬品工業株式会社 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
WO2020170355A1 (ja) 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Ｆｇｆｒ１変異腫瘍の治療方法
EP3932427A4 (en) 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. CANCER THERAPY USING A 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND AND PEMBROLIZUMAB
MA56549A (fr) 2019-06-21 2022-04-27 Taiho Pharmaceutical Co Ltd Méthode de traitement d'une tumeur maligne

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021167346A (ja) * 2018-03-19 2021-10-21 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
JP7322103B2 (ja) 2018-03-19 2023-08-07 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物

Also Published As

Publication number Publication date
KR102473372B1 (ko) 2022-12-05
KR20200131873A (ko) 2020-11-24
SG11202008435SA (en) 2020-10-29
PT3769765T (pt) 2024-05-13
MA52093A (fr) 2021-01-27
EP4470621A2 (en) 2024-12-04
WO2019181876A1 (ja) 2019-09-26
PH12020551412A1 (en) 2021-09-01
BR112020018697A2 (pt) 2020-12-29
JP7322103B2 (ja) 2023-08-07
EP3769765A1 (en) 2021-01-27
CN111867594A (zh) 2020-10-30
JPWO2019181876A1 (ja) 2020-10-08
US20210030755A1 (en) 2021-02-04
HUE067430T2 (hu) 2024-10-28
ES2980333T3 (es) 2024-09-30
US11833151B2 (en) 2023-12-05
TW201938564A (zh) 2019-10-01
JP2021167346A (ja) 2021-10-21
MY203305A (en) 2024-06-23
EP3769765B1 (en) 2024-04-17
AU2019239404A1 (en) 2020-11-05
DK3769765T3 (da) 2024-05-13
MX2020009762A (es) 2021-01-08
PL3769765T3 (pl) 2024-06-10
AU2019239404B2 (en) 2021-12-23
RU2759746C1 (ru) 2021-11-17
EP3769765A4 (en) 2021-12-15
EP4353222A1 (en) 2024-04-17
CA3094431C (en) 2023-06-27
CA3094431A1 (en) 2019-09-26
TWI790364B (zh) 2023-01-21
EP4470621A3 (en) 2025-05-07
FI3769765T3 (fi) 2024-05-15

Similar Documents

Publication Publication Date Title
JP6918204B2 (ja) アルキル硫酸ナトリウムを含む医薬組成物
ES2988678T3 (es) Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
JP5801826B2 (ja) ダビガトランエテキシラートを含有する経口用医薬組成物
US11413295B2 (en) Oral preparation of obeticholic acid
WO2013147134A1 (ja) ミラベグロン含有医薬組成物
US20220347102A1 (en) Pharmaceutical composition comprising enzalutamide
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
WO2021106004A1 (en) Pharmaceutical composition of s-adenosylmethionine
JP2022113667A (ja) エドキサバン含有医薬組成物
JP7271869B2 (ja) レボセチリジン含有錠剤
EP4623916A1 (en) Oral solid formulation
JP2007063217A (ja) プランルカスト水和物含有錠及びその製造方法
JP5563371B2 (ja) クエチアピンフマル酸塩含有経口用錠剤
HK40038943A (en) Pharmaceutical composition including sodium alkyl sulfate
WO2023238929A1 (ja) ピミテスピブを含有する医薬組成物
JPWO2014046129A1 (ja) 溶出性及び／又は吸収性が改善された経口投与用医薬組成物
JP2018002659A (ja) ゲフィチニブを有効成分とする医薬組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210622

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210720

R150 Certificate of patent or registration of utility model

Ref document number: 6918204

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250